Bioactivity of the cannabigerol cannabinoid and its analogues – the role of 3-dimensional conformation

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• Bioactivity of the cannabigerol cannabinoid and its analogues - the role of 3-dimensional conformation May 24, 2023 Org Biomol Chem. 2023 May 24. doi: 10.1039/d3ob00383c. Online ahead of print.ABSTRACTCannabinoids are naturally occurring bioactive compounds with the potential to help treat chronic illnesses including epilepsy, Parkinson's disease, dementia and multiple sclerosis. Their general structures and efficient syntheses are well documented in the literature, yet their quantitative structure-activity relationships (QSARs), particularly 3-dimensional (3-D) conformation-specific bioactivities, are not fully resolved.…
• Bioactivity of the cannabigerol cannabinoid and its analogues - the role of 3-dimensional conformation May 24, 2023 Org Biomol Chem. 2023 May 24. doi: 10.1039/d3ob00383c. Online ahead of print.ABSTRACTCannabinoids are naturally occurring bioactive compounds with the potential to help treat chronic illnesses including epilepsy, Parkinson's disease, dementia and multiple sclerosis. Their general structures and efficient syntheses are well documented in the literature, yet their quantitative structure-activity relationships (QSARs), particularly 3-dimensional (3-D) conformation-specific bioactivities, are not fully resolved.…
• Bioactivity of the cannabigerol cannabinoid and its analogues - the role of 3-dimensional conformation May 24, 2023 Org Biomol Chem. 2023 May 24. doi: 10.1039/d3ob00383c. Online ahead of print.ABSTRACTCannabinoids are naturally occurring bioactive compounds with the potential to help treat chronic illnesses including epilepsy, Parkinson's disease, dementia and multiple sclerosis. Their general structures and efficient syntheses are well documented in the literature, yet their quantitative structure-activity relationships (QSARs), particularly 3-dimensional (3-D) conformation-specific bioactivities, are not fully resolved.…
• Bioactivity of the cannabigerol cannabinoid and its analogues - the role of 3-dimensional conformation May 24, 2023 Org Biomol Chem. 2023 May 24. doi: 10.1039/d3ob00383c. Online ahead of print.ABSTRACTCannabinoids are naturally occurring bioactive compounds with the potential to help treat chronic illnesses including epilepsy, Parkinson's disease, dementia and multiple sclerosis. Their general structures and efficient syntheses are well documented in the literature, yet their quantitative structure-activity relationships (QSARs), particularly 3-dimensional (3-D) conformation-specific bioactivities, are not fully resolved.…
• Bioactivity of the cannabigerol cannabinoid and its analogues - the role of 3-dimensional conformation May 24, 2023 Org Biomol Chem. 2023 May 24. doi: 10.1039/d3ob00383c. Online ahead of print.ABSTRACTCannabinoids are naturally occurring bioactive compounds with the potential to help treat chronic illnesses including epilepsy, Parkinson's disease, dementia and multiple sclerosis. Their general structures and efficient syntheses are well documented in the literature, yet their quantitative structure-activity relationships (QSARs), particularly 3-dimensional (3-D) conformation-specific bioactivities, are not fully resolved.…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• The Llama-nation of LRRK2 April 8, 2022 # # # # Antibodies are tiny y-shaped markers used by the immune system to label foreign agents within the body. Once bound to something, antibodies can alert immune cells to come and remove the object. Antibodies can also inhibit the object from doing anything nasty, like infecting or damaging a cell. Between species, different types of antibodies have been…
• ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
• Speech, Voice & Parkinson’s Q&A with John Dean January 28, 2021 We recently hosted a webinar with speech-language pathologist John Dean. You can get access to the recording here. We received so many questions during the session that we weren’t able to answer them all; so, John was kind enough to do some written Q&A for us. “When is a good time to start speech therapy?” It’s much better to maintain…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Update on Complementary and Alternative Medicine (CAM) Therapy in Parkinson’s May 21, 2023 “The art of healing comes from nature, not from the physician. Therefore the physician must start from nature, with an open mind.” Paracelsus “You know what they call alternative medicine that’s been proved to work? – Medicine.” Tim Minchin Précis: Regularly, I am asked what I take for treating Parkinson’s. This blog post describes the various substances I take to…
• 'Sunday Morning Futures' on Biden's mental capacity, Jill Biden comparing Latinos to tacos August 1, 2022 This is a rush transcript from "Sunday Morning Futures" July 17, 2022. This copy may not be in its final form and may be updated.MARIA BARTIROMO, FOX NEWS ANCHOR: Good Sunday morning, everyone. Welcome to "Sunday Morning Futures." Thanks so much for joining us. I'm Maria Bartiromo. Today: weakness on the world stage. President Biden coming home from the Middle East…
• The Brilliant 10: The top up-and-coming minds in science October 19, 2022 Popular Science There’s a phrase that rings loudly in the heads of Popular Science editors any time we bring together a new Brilliant 10 class: “They’ve only just begun.” Our annual list of early-career scientists and engineers is as much a celebration of what our honorees have already accomplished as it is a forecast for what they’ll do next. To…
• Repurposing bumetanide for Alzheimer’s October 15, 2021 # # # # Bumetanide (Bumex) is a diuretic drug (a medication that removes water, by increasing the production of urine). It is used to treat swelling caused by heart failure or liver or kidney disease. It is a widely used drug that has been well characterised in clinical use. Recently researchers conducted a screening study to identify clinically available…
• UCB at ANN looks A-OK April 26, 2021 # # # # Alpha synuclein is one of the most common proteins in our brains and it has long been associated with Parkinson’s. The protein appears to clump together forming dense clusters ( or “aggregates“) in the Parkinsonian brain, and this may be related to the progressive neurodegeneration. Researchers have been desperately seeking small molecules that will break up…
• La Asociación Americana de Enfermedad de Parkinson lanza la App Diario de síntomas en con funciones ampliadas November 18, 2020 La App es fácil de usar y ayuda a las personas con la enfermedad de Parkinson realizar un seguimiento de sus síntomas y comunicarse con su equipo de atención médica ¡Una versión en español está disponible! NEW YORK, NY – 18 de noviembre de 2020. The American Parkinson Disease Association (la Asociación Americana de Enfermedad de Parkinson o APDA )…
• La Asociación Americana de Enfermedad de Parkinson lanza la App Diario de síntomas en con funciones ampliadas November 18, 2020 La App es fácil de usar y ayuda a las personas con la enfermedad de Parkinson realizar un seguimiento de sus síntomas y comunicarse con su equipo de atención médica ¡Una versión en español está disponible! NEW YORK, NY – 18 de noviembre de 2020. The American Parkinson Disease Association (la Asociación Americana de Enfermedad de Parkinson o APDA )…
• PARP-kinson’s goes chlorogenic December 20, 2020 # # # # For a long time it was been reported that coffee may be able to reduce the risk of developing Parkinson’s, but the mechansim by which this association could be occurring has remained elusive. Now researchers from South Korea have discovered a biological pathway that could help to explain the protective association. It involves a protein called…
• Six Pillars of Parkinson’s December 11, 2022 “In all human affairs there are efforts, and there are results, and the strength of the effort is the measure of the result.” James Allen “Storms make trees take deeper roots.” Dolly Parton NOTE ADDED IN PROOF: Earlier today, I inadvertently published this post’s unfinished and unproofed version. It was titled “6 Pillars of Parkinson’s.” I apologize for pushing the…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…